Metrion Biosciences announces launch of Good Laboratory Practice (GLP) hERG Screening Service

Metrion Biosciences Limited (“Metrion”), the specialist ion channel contract research and drug discovery company, today announced it has received notification from the UK’s Medicines and Healthcare Products Regulatory Agency (MHRA) that the Company is now a member of the UK GLP (Good Laboratory Practice) Compliance Monitoring Programme, and is, therefore, able to offer GLP compliant hERG ion channel screening services to the global life sciences community.

GLP hERG screening is a vital step in the transition from preclinical research to Phase 1 clinical trials in humans, regardless of the therapeutic target class. Pharmacological assessments against the human ether-à-go-go related gene (hERG) potassium channel, conducted in compliance with GLP principles and adhering to ICH S7A and ICH S7B guidelines, is an important step in the Investigational New Drug (IND) application process for potential small molecule therapeutics.

Metrion has offered hERG profiling services since the Company was founded in 2015 and has since expanded its cardiac safety offer to include a full panel of Comprehensive in Vitro Proarrhythmia Assay (CiPA) services. The addition of the new GLP hERG service further strengthens the Company’s suite of cardiac safety screening assays, providing a substantial range of options to assess potential cardiac liabilities as preclinical discovery research programs are progressed.

Metrion’s expanding portfolio of ion channel services now includes the new GLP hERG assays in addition to high throughput screening (HTS) in both automated electrophysiology and fluorescence formats, a comprehensive ion channel cell biology capability, translational assays, and significant expertise for neuroscience drug discovery research.

The launch of our GLP hERG screening capability adds further depth to our ion channel drug discovery services and complements our existing cardiac safety service portfolio. Our team is pleased to be able to offer GLP quality services to new and existing clients globally as we continue to develop Metrion as a leading ion channel-focused CRO.

Dr. Andrew Southan, Chief Executive of Metrion Biosciences

For more information: https://www.metrionbiosciences.com/

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Metrion Biosciences Limited. (2023, August 07). Metrion Biosciences announces launch of Good Laboratory Practice (GLP) hERG Screening Service. News-Medical. Retrieved on April 15, 2024 from https://www.news-medical.net/news/20230807/Metrion-Biosciences-announces-launch-of-Good-Laboratory-Practice-(GLP)-hERG-Screening-Service.aspx.

  • MLA

    Metrion Biosciences Limited. "Metrion Biosciences announces launch of Good Laboratory Practice (GLP) hERG Screening Service". News-Medical. 15 April 2024. <https://www.news-medical.net/news/20230807/Metrion-Biosciences-announces-launch-of-Good-Laboratory-Practice-(GLP)-hERG-Screening-Service.aspx>.

  • Chicago

    Metrion Biosciences Limited. "Metrion Biosciences announces launch of Good Laboratory Practice (GLP) hERG Screening Service". News-Medical. https://www.news-medical.net/news/20230807/Metrion-Biosciences-announces-launch-of-Good-Laboratory-Practice-(GLP)-hERG-Screening-Service.aspx. (accessed April 15, 2024).

  • Harvard

    Metrion Biosciences Limited. 2023. Metrion Biosciences announces launch of Good Laboratory Practice (GLP) hERG Screening Service. News-Medical, viewed 15 April 2024, https://www.news-medical.net/news/20230807/Metrion-Biosciences-announces-launch-of-Good-Laboratory-Practice-(GLP)-hERG-Screening-Service.aspx.

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment
Post

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Metrion Biosciences expands ion channel drug discovery service capabilities and in-house expertise